BYETTA
BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus. It is used as an adjunct to diet and exercise in this patient population. The medication is not recommended for coadministration with other products containing exenatide. Its therapeutic role is to reduce both fasting and postprandial glucose concentrations.
How BYETTA Works
BYETTA functions by binding to and activating the human GLP-1 receptor, which enhances glucose-dependent insulin synthesis and secretion from pancreatic beta cells. The drug also suppresses inappropriately elevated glucagon secretion and slows the rate of gastric emptying. These combined actions lead to a reduction in blood glucose levels. These effects are mediated through intracellular signaling pathways involving cyclic AMP.
Details
- Status
- Prescription
- First Approved
- 2005-04-28
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
BYETTA Approval History
What BYETTA Treats
1 indicationsBYETTA is approved for 1 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Type 2 diabetes mellitus
BYETTA Target & Pathway
ProTarget
A hormone released after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists mimic these effects, improving blood sugar control and promoting weight loss in diabetes and obesity.
BYETTA Competitors
Pro6 other drugs also target GLP-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (GLP-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to BYETTA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BYETTA FDA Label Details
ProIndications & Usage
FDA Label (PDF)BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • Coadministration with other exenatide-containing products is not recommended .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.